Polaris Industries ((PII)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Polaris Industries is currently conducting a clinical study titled ‘A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of ADI-PEG 20 or Placebo in Subjects With Nonalcoholic Steatohepatitis (NASH)’. The study aims to evaluate the efficacy and safety of the drug ADI-PEG 20 in treating patients with NASH, a significant liver condition. This research is crucial as it could lead to new therapeutic options for NASH, a disease with limited treatment choices.
The intervention being tested is ADI-PEG 20, a drug administered intramuscularly at a dose of 36 mg/m2 weekly. The purpose of this drug is to treat NASH by potentially reducing liver inflammation and damage.
The study is designed as an interventional trial with a randomized allocation and a parallel intervention model. It employs a triple masking approach, meaning that the participant, care provider, and investigator are all blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on January 20, 2023, with an estimated primary completion date yet to be announced. The last update was submitted on September 18, 2025. These dates are important as they indicate the study’s progress and timelines for potential results.
This clinical update could influence Polaris Industries’ stock performance positively, as successful results may enhance investor confidence and market position. The study’s progress is particularly relevant in the context of the competitive pharmaceutical industry, where advancements in NASH treatment are highly sought after.
The study is ongoing, with further details available on the ClinicalTrials portal.